rood blauwe elepsis logo Belegger.nl

GALAPAGOS SEPTEMBER 2018

6.351 Posts
Pagina: «« 1 ... 207 208 209 210 211 ... 318 »» | Laatste | Omlaag ↓
  1. forum rang 4 Jonge_belegger 13 september 2018 22:02
    quote:

    MrBerth schreef op 13 september 2018 22:01:

    Nasdaq sluit 88 eurocent hoger dan slotkoers euronext! Met een volume >1.2 miljoen! Wat is daar aan de hand!
    En zo goed als DH. Denk dat we bij de opening morgen meer weten ;)
  2. Föhn 13 september 2018 22:04
    quote:

    Jonge_belegger schreef op 13 september 2018 22:00:

    [...]
    Dan komt het binnen nu en 10 min. Dus droom verder ;)
    Dat zei je eergisteren ook Jonge Belegger...
  3. Sentiment 13 september 2018 22:04
    Galapagos NV (Euronext & NASDAQ: GLPG) en MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) hebben vandaag de start aangekondigd van een Fase 1 overbruggingsstudie voor het onderzoeken van een subcutane formulering van MOR106, een antilichaam in ontwikkeling gericht tegen IL-17C.
  4. [verwijderd] 13 september 2018 22:04
    quote:

    MrBerth schreef op 13 september 2018 22:01:

    Nasdaq sluit 88 eurocent hoger dan slotkoers euronext! Met een volume >1.2 miljoen! Wat is daar aan de hand!
    Zeer apart ja
  5. [verwijderd] 13 september 2018 22:06
    Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
    13 September 2018 at 22:01 CET
    Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.

    This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, randomized, open-label study in healthy volunteers who will be treated with different single dose levels of MOR106 administered subcutaneously or intravenously. Part 2 is a multiple center, randomized, placebo-controlled, multiple dose study in patients with moderate to severe atopic dermatitis who will be treated subcutaneously for 12 weeks.

    Safety and tolerability, pharmacokinetics (PK) and occurrence of anti-drug-antibodies after administration of MOR106 will be assessed as endpoints. In addition, the efficacy of MOR106 will be explored in subjects with moderate to severe atopic dermatitis.

    "The start of the bridging study together with Galapagos with a subcutaneous formulation of MOR106 is an important milestone in its clinical development," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "This route of subcutaneous administration is widely used for the treatment of chronic skin diseases, and we intend to evaluate it in this study with the goal of providing support for the further clinical development of MOR106."

    "This study represents the next important step in our strategy to progress MOR106 rapidly in the clinic and is expected to provide additional insights into patient response, while we await the results of our ongoing IGUANA Phase 2 trial with MOR106 in atopic dermatitis patients," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.

    MOR106 was generated using MorphoSys's Ylanthia antibody platform and is based on a target discovered by Galapagos. IL-17C is a cytokine expressed preferentially in the skin and which has been implicated in dermal inflammation and shown to be distinct from other members of the IL-17 cytokine family. MOR106 is the first publicly known human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is an investigational drug and its safety and efficacy have not yet been established. Novartis Pharma AG owns the worldwide, exclusive license for the development and commercialization of MOR106 under an agreement with MorphoSys and Galapagos which became effective on September 10, 2018.
  6. aloha28 13 september 2018 22:07
    quote:

    Rachmaninow schreef op 13 september 2018 21:59:

    Vannacht bod , slaap lekker allemaal.
    als dat zo is blijf ik wakker.
  7. forum rang 7 bezinteergebelegt 13 september 2018 22:08
    quote:

    MrBerth schreef op 13 september 2018 22:01:

    Nasdaq sluit 88 eurocent hoger dan slotkoers euronext! Met een volume >1.2 miljoen! Wat is daar aan de hand!

    Edit: 83 cent hoger
    Tegen E/D is slot daar 102,30.

    Niks bijzonders dus.
  8. forum rang 4 Jonge_belegger 13 september 2018 22:10
    quote:

    Föhn schreef op 13 september 2018 22:04:

    [...]

    Dat zei je eergisteren ook Jonge Belegger...
    Klopt.. moet ik je gelijk in geven. Maar vanavond geen bod.
  9. Föhn 13 september 2018 22:11
    quote:

    Jonge_belegger schreef op 13 september 2018 22:10:

    [...]
    Klopt.. moet ik je gelijk in geven. Maar vanavond geen bod.
    Mee eens. Maar voldoende reuring in de tent. Zonder bod vermaak ik me ook wel zo.
  10. [verwijderd] 13 september 2018 22:13
    quote:

    bezinteergebelegt schreef op 13 september 2018 22:08:

    [...]

    Tegen E/D is slot daar 102,30.

    Niks bijzonders dus.
    $120.22(1) is omgerekend €102,82 (2) een plus van €0,82(3)

    (1) m.nl.investing.com/equities/galapagos...

    (2) www.x-rates.com/calculator/?from=USD&...

    (3) www.euronext.com/nl/products/equities...
  11. d8v1nc1 13 september 2018 22:13
    quote:

    durobinet schreef op 13 september 2018 22:06:

    Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
    13 September 2018 at 22:01 CET
    Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.

    This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, randomized, open-label study in healthy volunteers who will be treated with different single dose levels of MOR106 administered subcutaneously or intravenously. Part 2 is a multiple center, randomized, placebo-controlled, multiple dose study in patients with moderate to severe atopic dermatitis who will be treated subcutaneously for 12 weeks.

    Safety and tolerability, pharmacokinetics (PK) and occurrence of anti-drug-antibodies after administration of MOR106 will be assessed as endpoints. In addition, the efficacy of MOR106 will be explored in subjects with moderate to severe atopic dermatitis.

    "The start of the bridging study together with Galapagos with a subcutaneous formulation of MOR106 is an important milestone in its clinical development," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "This route of subcutaneous administration is widely used for the treatment of chronic skin diseases, and we intend to evaluate it in this study with the goal of providing support for the further clinical development of MOR106."

    "This study represents the next important step in our strategy to progress MOR106 rapidly in the clinic and is expected to provide additional insights into patient response, while we await the results of our ongoing IGUANA Phase 2 trial with MOR106 in atopic dermatitis patients," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos.

    MOR106 was generated using MorphoSys's Ylanthia antibody platform and is based on a target discovered by Galapagos. IL-17C is a cytokine expressed preferentially in the skin and which has been implicated in dermal inflammation and shown to be distinct from other members of the IL-17 cytokine family. MOR106 is the first publicly known human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is an investigational drug and its safety and efficacy have not yet been established. Novartis Pharma AG owns the worldwide, exclusive license for the development and commercialization of MOR106 under an agreement with MorphoSys and Galapagos which became effective on September 10, 2018.
    Dit is weer goed nieuws! Pipeline draait op volle toeren :-)
  12. Koperlijktopgoud 13 september 2018 22:15
    Ben toch benieuwd wat Gilead nu denkt. Die zullen toch een reactie moeten geven.
    Nog even en onno heeft zijn muurtje
    Hij is goed vooraan het sorteren
    Dit weekend of volgend weekend een reactie van Gilead een laag bod 180 euro
    Flesje wijn erop!
6.351 Posts
Pagina: «« 1 ... 207 208 209 210 211 ... 318 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.529
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.949
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.807
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.782
Aedifica 3 925
Aegon 3.258 323.007
AFC Ajax 538 7.088
Affimed NV 2 6.301
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.249
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.104
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.630
AMG 971 134.099
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.031
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.342
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.550
ASR Nederland 21 4.505
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.733
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.438